1. Home
  2. PODD vs ASX Comparison

PODD vs ASX Comparison

Compare PODD & ASX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PODD
  • ASX
  • Stock Information
  • Founded
  • PODD 2000
  • ASX 1984
  • Country
  • PODD United States
  • ASX Taiwan
  • Employees
  • PODD N/A
  • ASX N/A
  • Industry
  • PODD Medical/Dental Instruments
  • ASX Semiconductors
  • Sector
  • PODD Health Care
  • ASX Technology
  • Exchange
  • PODD Nasdaq
  • ASX Nasdaq
  • Market Cap
  • PODD 21.5B
  • ASX 22.0B
  • IPO Year
  • PODD 2007
  • ASX 1995
  • Fundamental
  • Price
  • PODD $292.01
  • ASX $10.21
  • Analyst Decision
  • PODD Strong Buy
  • ASX Strong Buy
  • Analyst Count
  • PODD 19
  • ASX 1
  • Target Price
  • PODD $320.11
  • ASX N/A
  • AVG Volume (30 Days)
  • PODD 753.8K
  • ASX 11.6M
  • Earning Date
  • PODD 08-07-2025
  • ASX 07-24-2025
  • Dividend Yield
  • PODD N/A
  • ASX 2.58%
  • EPS Growth
  • PODD 67.46
  • ASX 6.14
  • EPS
  • PODD 5.55
  • ASX 0.23
  • Revenue
  • PODD $2,198,900,000.00
  • ASX $18,355,472,366.00
  • Revenue This Year
  • PODD $24.49
  • ASX $12.29
  • Revenue Next Year
  • PODD $17.45
  • ASX $11.92
  • P/E Ratio
  • PODD $52.60
  • ASX $21.27
  • Revenue Growth
  • PODD 23.48
  • ASX 4.61
  • 52 Week Low
  • PODD $173.00
  • ASX $6.94
  • 52 Week High
  • PODD $329.33
  • ASX $12.04
  • Technical
  • Relative Strength Index (RSI)
  • PODD 38.75
  • ASX 50.63
  • Support Level
  • PODD $289.03
  • ASX $9.92
  • Resistance Level
  • PODD $300.00
  • ASX $10.59
  • Average True Range (ATR)
  • PODD 7.17
  • ASX 0.20
  • MACD
  • PODD -1.98
  • ASX -0.05
  • Stochastic Oscillator
  • PODD 11.05
  • ASX 35.62

About PODD Insulet Corporation

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetics are using it worldwide.

About ASX ASE Technology Holding Co. Ltd. (each representing Two)

ASE Technology Holding Co Ltd is a semiconductor assembly and testing firm. The company operates in segments: Packaging, Testing, and Electronic Manufacturing Services. Of these, Packaging segment contribute the maximum revenue. The packaging segment involves packaging bare semiconductors into completed semiconductors with improved electrical and thermal characteristics. The Testing Segment includes front-end engineering testing, wafer probing, and final testing services. In the EMS segment, the company designs manufactures, and sells electronic components and telecommunication equipment motherboards. The company is based in Taiwan but garners over half its sales from firms in the United States.

Share on Social Networks: